DavidH.VesoleMDPhD

Co-Chief, Myeloma Division; Director, Myeloma Research, John Theurer Cancer Center; Director, Myeloma Program, Medstar Georgetown University Hospital

Join to view full profile

Dr. Vesole is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vesole's full profile

Already have an account?

Office
92 2nd St
Hackensack, NJ 07601
Phone+1 551-996-8704

Fax+1 551-996-0582

Summary

David H. Vesole, MD, PhD, FACP
Co-Director, Myeloma Division; Director, Myeloma Research
John Theurer Cancer Center at Hackensack University Medical Center
Professor of Medicine, Georgetown University
Director, Multiple Myeloma Program

David H. Vesole completed a medical degree at Northwestern University and a doctorate in immunology and microbiology at the Medical University of South Carolina. His postdoctoral training included a residency in internal medicine and a fellowship in Hematology and Oncology at University of Iowa Hospitals and Clinics. Dr. Vesole is Co-Director, Myeloma Division and Director, Myeloma research at the John Theurer Cancer Center at Hackensack University Medical Center. He is Professor of Medicine at Georgetown University where he is Director, Myeloma Program. Dr. Vesole previously was the Director, BMT Program Loyola University in Maywood, IL, an attending physician at St. Vincent's Comprehensive Cancer Center in New York and Professor of Medicine and Clinical Director of the Blood and Marrow Transplant Program at the Medical College of Wisconsin in Milwaukee, WI.

Board certified in medical oncology and hematology and a Fellow of the American College of Physicians, Dr. Vesole is active in several professional organizations, including the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology and the American Society of Hematology. He previously served as Co-chair of the Eastern Cooperative Oncology Group Myeloma Committee and the Center for International Blood and Marrow Transplant Research (CIBMTR) Plasma Cell Disorder Committee. He was on the Nominating Committee for the CIBMTR. He is a Foundation for the Accreditation of Cellular Therapy (FACT) inspector and serves on the Clinical Standards, Accreditation and Data Management Task Force Committees for FACT. He is a member of the International Myeloma Working Group.

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1987 - 1990
University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1984

Certifications & Licensure

DC State Medical License 2012 - 2027
NY State Medical License 2005 - 2027
MD State Medical License 2018 - 2025
NJ State Medical License 2009 - 2025
IL State Medical License 1985 - 2011
WI State Medical License 1996 - 2009
IA State Medical License 1984 - 2005
AR State Medical License 1990 - 2004
American Board of Internal Medicine Internal Medicine
ABIMHematology
ABIMMedical Oncology
Join now to see all

Awards, Honors, & Recognition

Board Member Leukemia Lymphoma Society, New York
Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2014
Top Doctors: New York Metro Area Castle Connolly, 2010-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Inside Jersey Top Doctors for Cancer Castle Connolly, 2012
Join now to see all

Clinical Trials

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Start of enrollment: 1997 Sep 01
Unknown status
Phase 2
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 08
Completed
Phase 3
PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Start of enrollment: 2010 Jun 16
Terminated
Phase 3
Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older Start of enrollment: 2010 Jun 24
Terminated
Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Start of enrollment: 2010 Jun 09
Completed
Phase 2
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Start of enrollment: 2013 Feb 01
Completed
Phase 1
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Start of enrollment: 2013 Apr 01
Completed
Phase 2
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Dec 06
Active, not recruiting
Phase 3
Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia Start of enrollment: 2014 Jul 07
Completed
Phase 3
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma Start of enrollment: 2015 Jan 21
Active, not recruiting
Phase 1
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Start of enrollment: 2015 Aug 01
Completed
Phase 2
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence Start of enrollment: 2016 Jun 07
Terminated
Phase 1, Phase 2
PRospective Multiple Myeloma Impact Study Start of enrollment: 2018 Feb 27
Active, not recruiting
Not Applicable
Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma Start of enrollment: 2017 Oct 25
Completed
Phase 1
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2019 Oct 08
Suspended
Phase 1
Join now to see all

Publications & Presentations

PubMed

Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost.
Ayrton Bangolo, Samir Oza, Ronit Reich-Slotky, Aimee Chappell, David S Siegel
Current Stem Cell Research & Therapy. 2025-01-01
Venetoclax in the Treatment of Multiple Myeloma: A Retrospective Analysis of 79 Patients.
Eli Zolotov, Vanisha Patel, Yedidyah Weiss, Noa Biran, Pooja Phull
European Journal of Haematology. 2024-12-05
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression.
Charalampos Charalampous, Kimberley Doucette, Aimee Chappell, David H Vesole
Leukemia & Lymphoma. 2024-12-01

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...
Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Abstracts/Posters

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 Patients
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Elotuzumab As Post-Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Myeloma
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Recent Advancements and Future Directions in Frontline Treatment of Multiple MyelomaJuly 11th, 2022
John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual ConferenceDecember 9th, 2021
John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100August 4th, 2017
Join now to see all

Committees

Member, ASCO Plasma Cell Educational Committee 2015 - Present
Member, ASCO Clinical Practice Guidelines Committee 2015 - Present
Nominating Committee, American Society of Blood and Marrow Transplant 2015 - Present
Data Audit Committee, Federation for The Accreditation of Cellular Therapy 2014 - Present
Accreditation Committee, Federation for The Accreditation of Cellular Therapy
Clinical Standards Committee, Federation for The Accreditation of Cellular Therapy
Scientific Advisory Committee, International Myeloma Foundation
Myeloma Committee, Blood and Marrow Transplant Clinical Trials Network